Liang Zhao

Dr. Liang Zhao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
LZLiang Zhao
Liang Zhao
JZJiayue Zhang
Jiayue Zhang
ZLZhiyuan Liu
Zhiyuan Liu
YWYu Wang
Yu Wang
SXShurui Xuan
Shurui Xuan
PZPeng Zhao
Peng Zhao
Alternative splicing (AS) of pre-mRNA has been widely reported to be associated with the progression of malignant tumors. However, a systematic investigation into the prognostic value of AS events in glioblastoma (GBM) is urgently required. The gene expression profile and matched AS events data of GBM patients were obtained from The Cancer Genome Atlas Project (TCGA) and TCGA SpliceSeq database, respectively. 775 AS events were identified as prognostic factors using univariate Cox regression analysis. The least absolute shrinkage and selection operator (LASSO) cox model was performed to narrow down candidate AS events, and a risk score model based on several AS events were developed subsequently. The risk score-based signature was proved as an efficient predictor of overall survival and was closely related to the tumor purity and immunosuppression in GBM. Combined similarity network fusion and consensus clustering (SNF-CC) analysis revealed two distinct GBM subtypes based on the prognostic AS events, and the associations between this novel molecular classification and clinicopathological factors, immune cell infiltration, as well as immunogenic features were further explored. We also constructed a regulatory network to depict the potential mechanisms that how prognostic splicing factors (SFs) regulate splicing patterns in GBM. Finally, a nomogram incorporating AS events signature and other clinical-relevant covariates was built for clinical application. This comprehensive analysis highlights the potential implications for predicting prognosis and clinical management in GBM.

17 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
SXShurui Xuan
Shurui Xuan
JZJiayue Zhang
Jiayue Zhang
QGQinxing Guo
Qinxing Guo
LZLiang Zhao
Liang Zhao
XYXin Yao
Xin Yao
Chronic obstructive pulmonary disease (COPD) is highly underdiagnosed, and early detection is urgent to prevent advanced progression. Circulating microRNAs (miRNAs) have been diagnostic candidates for multiple diseases. However, their diagnostic value has not yet been fully established in COPD. The purpose of this study was to develop an effective model for the diagnosis of COPD based on circulating miRNAs. We included circulating miRNA expression profiles of two independent cohorts consisting of 63 COPD and 110 normal samples, and then we constructed a miRNA pair-based matrix. Diagnostic models were developed using several machine learning algorithms. The predictive performance of the optimal model was validated in our external cohort. In this study, the diagnostic values of miRNAs based on the expression levels were unsatisfactory. We identified five key miRNA pairs and further developed seven machine learning models. The classifier based on LightGBM was selected as the final model with the area under the curve (AUC) values of 0.883 and 0.794 in test and validation datasets, respectively. We also built a web tool to assist diagnosis for clinicians. Enriched signaling pathways indicated the potential biological functions of the model. Collectively, we developed a robust machine learning model based on circulating miRNAs for COPD screening.

17 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
LZLiang Zhao
Liang Zhao
JZJiayue Zhang
Jiayue Zhang
SXShurui Xuan
Shurui Xuan
ZLZhiyuan Liu
Zhiyuan Liu
YWYu Wang
Yu Wang
PZPeng Zhao
Peng Zhao
Background: O6-methylguanine-DNA methyltransferase (MGMT) methylation status affects tumor chemo-resistance and the prognosis of glioblastoma (GBM) patients. We aimed to investigate the role of MGMT methylation in the regulation of GBM immunophenotype and discover an effective biomarker to improve prognosis prediction of GBM patients. Methods: A total of 769 GBM patients with clinical information from five independent cohorts were enrolled in the present study. Samples from the Cancer Genome Atlas (TCGA) dataset were used as the training set, whereas transcriptome data from the Chinese Glioma Genome Atlas (CGGA) RNA-seq, CGGA microarray, GSE16011, and the Repository for Molecular Brain Neoplasia (REMBRANDT) cohort were used for validation. A series of bioinformatics approaches were carried out to construct a prognostic signature based on immune-related genes, which were tightly related with the MGMT methylation status. The influence of the signature on immunosuppression and remodeling of the tumor microenvironment were comprehensively investigated. Then, the utility of this immune gene signature was analyzed by the development and evaluation of a nomogram. Results: We found that MGMT unmethylation was closely associated with immune-related biological processes in GBM. Sixty-five immune genes were more highly expressed in the MGMT unmethylated than the MGMT methylated group. An immune gene-based risk model was further established to divide patients into high and low-risk groups, and the prognostic value of this signature was validated in several GBM cohorts. Functional analyses manifested a universal up-regulation of immune-related pathways in the high-risk group as compared to the low-risk group. Furthermore, the risk score was highly correlated to the immune cell infiltration, immunosuppression, inflammatory activities, as well as the expression levels of immune checkpoints. Finally, a nomogram was developed for clinical application. Conclusions: MGMT methylation is strongly related to the immune responses in GBM. The immune gene-based signature we identified may have potential implications in predicting the prognosis of GBM patients and mechanisms underlying the role of MGMT methylation.

3 April 2023
Verified
Other
Open access
KLKathryn Lemberg
Kathryn Lemberg
LZLiang Zhao
Liang Zhao
YWYing Wu
Ying Wu
VVVijayabhaskar Veeravalli
Vijayabhaskar Veeravalli
JAJesse Alt
Jesse Alt
BSBarbara S. Slusher
Barbara S. Slusher
Supplemental Figure 1: JHU395 and DON treatment of sNF02.2 MPNST cells, evaluation of PARP cleavage following JHU395 treatment in sNF96.2 cells, and effects of DON and JHU395 on oxygen consumption rates in sNF96.2 MPNST cells.


3 April 2023
Verified
Other
Open access
KLKathryn Lemberg
Kathryn Lemberg
LZLiang Zhao
Liang Zhao
YWYing Wu
Ying Wu
VVVijayabhaskar Veeravalli
Vijayabhaskar Veeravalli
JAJesse Alt
Jesse Alt
BSBarbara S. Slusher
Barbara S. Slusher
Supplemental Table 1: List of significantly affected metabolites identified in volcano plot following JHU395 versus vehicle treatment of flank MPNST